In Biodefense Setting, Marking Progress of Newer Vaccine Platforms
Vaccines based on relatively newer platforms, including those that are DNA-based, consist of virus-like particles (VLP), or are microencapsulated, are making headway. Progress appears especially bright for vaccine candidates aimed in particular at protecting against viral or bacterial pathogens that are considered biodefense risks and sometimes demand unconventional approaches, according to several researchers who spoke during the symposium "Novel Vaccine Approaches," part of the 8th ASM Biodefense and Emerging Diseases Research Meeting, held in Baltimore, Md., last February.
VLP vaccines against the Ebola and Marburg viruses are proving effective in protecting mice and monkeys against otherwise lethal doses of these filoviruses, according to Kelly Warfield at Integrated Biotherapeutics in Germantown, Md. Typically, two doses are needed to protect animals against killing by a viral challenge. Based on experiments involving mice with genetically impaired immune systems, a host antibody response to the viral glycoprotein appears to be key for protection, she points out. The VLPs are produced using baculoviruses that grow in insect cells but which are engineered to carry one or several filovirus genes, including those encoding the envelope glycoprotein, the nuclear protein, and the VP40 matrix protein, she says. The VLPs are fully enveloped and similar in size and shape to active viruses, but are nonreplicating.
Electroporation, which involves use of electric fields to enhance delivery of DNA across tissue barriers, can improve the potency of DNA-based vaccines by as much as three orders of magnitude, according to Drew Hannamen of Ichor Medical Systems in San Diego, Calif. Ichor has developed and continues to evaluate a specialized device that delivers such vaccines either into muscle tissues or intradermally, he says. In a phase 1 clinical trial conducted late in 2009, the delivery device being developed by the company was used to administer a prototype HIV vaccine in 40 individuals. The test vaccination procedure produced no serious adverse effects, he says. However, the delivery produces a "slight burning sensation on the skin" when the DNA vaccine is directed intradermally, and something more like a "punch" when delivered intramuscularly.
Meanwhile, in experiments involving mice and macaques tested with DNA encoding the PA antigen of Bacillus anthracis, animals produced neutralizing antibodies after a single electroporation-delivered dose, and there was "very nice protection" among mice against a subsequent intratracheal challenge by B. anthracis, Hannamen says. The DNA vaccine delivery system also works well in macaques, protecting them against aerosol challenges of that bacterial pathogen. Moreover, the effect is long lasting, he adds. "After one year, we see complete protection."
Insights into Nitrogen-fixing Microorganisms, Their Hosts, or Other Partners
The genome sequence of a recently discovered, ocean-dwelling, nitrogen-fixing cyanobacterium, called UCYN-A, indicate that it is missing several core metabolic pathways, including components for the central trichloroacetic acid cycle as well as those for making purines and several amino acids, according to Jonathan Zehr of the University of California, Santa Cruz, and his collaborators. Its reduced genome, which is structurally similar to that found in chloroplasts and some bacteria, suggests it depends on other organisms for critical nutrients, they report. Details appear in the 4 March 2010 Nature (464:90 -94). Back on land, the interactions between nitrogen-fixing bacteria in the roots of their leguminous host plants appear to be more complex than once thought. Specifically, Sinorhizobium meliloti bacteria depend on an intact host signal peptidase to form a working symbiosis, according to Sharon Long of Stanford University and her collaborators. "These plants have a specialized protein processing system that generates specific protein signals," she says. "These were hitherto unknown, but it turns out they are critical to cause nitrogen fixation." Details appear in the 26 February 2010 Science (327:1126 -1129). Early this year, investigators completed a phase 1 clinical trial involving a DNA-based vaccine to protect against renal syndrome caused by hantavirus, according to Jay Hooper of USAMRIID at Fort Detrick in Frederick, Md. Infections caused by hantavirus, which is rodent-borne, can induce vascular leakage in either the kidneys or lungs, conditions that have about a 40% fatality rate, he says. The vaccine consists of a DNA plasmid carrying the hantavirus gene encoding one or another version of the surface glycoprotein of several distinct hantaviruses.
In the phase 1 trial, the vaccine was delivered via a handheld gene gun, with the plasmid DNA carried on powdered gold into the skin of recipients. Among the 28 participants, several experienced fatigue, headaches, malaise, or swelling of lymph nodes, but overall there were "no serious vaccine-related adverse events," Hooper says. Moreover, the vaccine elicited "high titers," and some recipients developed "neutralizing antibodies," whereas others developed "unexpected" antibody patterns that so far "can't be explained." The findings are encouraging enough, he adds, to warrant further clinical testing.
Another means for boosting efficiency and overcoming other problems depends on microencapsulating appropriate viral antigens within nanoparticles, according to Allison Ficht of Texas A&M University in College Station. Typically, those particles, which sometimes are made of chitosan, may range in sizes comparable to either large viral particles or small bacterial cells, she says. Microencapsulating antigens can increase efficacy and improve vaccine performance by one to two orders of magnitude. For one thing, the particles release antigens slowly, prolonging their stimulatory effects on the host immune system, she says. For another, they tend to interact initially with components of the innate immune system, triggering modulatory responses, such as transient release by macrophage cells of tumor necrosis factor. The approach is applicable to a wide range of antigens.
